ReSeqTB specifications

Information


Unique identifier OMICS_32526
Name ReSeqTB
Alternative name Relational Sequencing Tuberculosis Data Platform
Restrictions to use None
Community driven No
Data access Browse
User data submission Not allowed
Registration required Yes
Maintained No

Maintainer


This tool is not available anymore.

Publication for Relational Sequencing Tuberculosis Data Platform

ReSeqTB citations

 (2)
library_books

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis

2017
PMCID: 5898944
PMID: 29284687
DOI: 10.1183/13993003.01354-2017

[…] his study will be used as a standardised analytical approach for assessing potential resistance mutations in the Relational Sequencing TB Data Sharing Platform currently available at https://platform.reseqtb.org/. The ReSeqTB platform serves as a globally harmonised knowledge base for the curation, validation and interpretation of existing and newly created genotypic and phenotypic data for TB dru […]

library_books

Clinical use of whole genome sequencing for Mycobacterium tuberculosis

2016
PMCID: 4804576
PMID: 27004841
DOI: 10.1186/s12916-016-0598-2

[…] to become effective, validated and continuously updated databases need to be developed and made available; successful examples include the public HIV Drug Resistance Database []. The recently funded ReSeqTB project [], which aims to implement a single repository for validated TB drug-resistant correlations, may fulfil this role; however, it is still in the early stages of development. Furthermore […]

ReSeqTB institution(s)
Division of Tuberculosis Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA; Critical Path Institute, Tucson, AZ, USA; Istituti di Ricovero e Cura a Carattere Scientifico, San Raffaele Scientific Institute, Milan, Italy; Foundation for Innovative New Diagnostics, Geneva, Switzerland; Centre for Ethical, Social, and Cultural Risk, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto, ON, Canada; Bill & Melinda Gates Foundation, Seattle, WA, USA; Division of AIDS, National Institute of Allergy and Infectious Diseases,National Institutes of Health, Bethesda, MD, USA; Global TB Programme, TB Monitoring and Evaluation, World Health Organization, Geneva, Switzerland
ReSeqTB funding source(s)
Supported by the Bill & Melinda Gates Foundation to Foundation for Innovative New Diagnostics (FIND) (grant number OPP1115209) and the Critical Path Institute (grant number OPP1115887).

ReSeqTB reviews

star_border star_border star_border star_border star_border
star star star star star

Be the first to review ReSeqTB